|
Mar 29
|
Why Ultragenyx Pharmaceutical (RARE) Is Among the Best Mid Cap Biotech Stocks to Buy
|
|
Feb 21
|
Exploring Three High Growth Tech Stocks in the United States
|
|
Feb 18
|
Ultragenyx Announces FDA Acceptance and Priority Review of the Biologics License Application (BLA) for UX111 AAV Gene Therapy to Treat Sanfilippo Syndrome Type A (MPS IIIA)
|
|
Feb 15
|
Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Just Reported Yearly Earnings: Have Analysts Changed Their Mind On The Stock?
|
|
Feb 14
|
Q4 2024 Ultragenyx Pharmaceutical Inc Earnings Call
|
|
Feb 14
|
Ultragenyx Q4 Loss Wider Than Expected, Revenues Increase Y/Y
|
|
Feb 14
|
Ultragenyx Pharmaceutical Inc (RARE) Q4 2024 Earnings Call Highlights: Strong Revenue Growth ...
|
|
Feb 13
|
Ultragenyx: Q4 Earnings Snapshot
|
|
Feb 13
|
Ultragenyx Reports Fourth Quarter and Full Year 2024 Financial Results and Corporate Update
|
|
Oct 23
|
Recent 4.1% pullback isn't enough to hurt long-term Ultragenyx Pharmaceutical (NASDAQ:RARE) shareholders, they're still up 70% over 1 year
|
|
Sep 26
|
Ultragenyx Announces Upcoming Setrusumab (UX143) Presentations at the ASBMR 2024 Annual Meeting
|
|
Aug 29
|
Ultragenyx to Participate in Investor Conferences in September
|
|
Jul 25
|
Ultragenyx to Host Conference Call for Second Quarter 2024 Financial Results and Corporate Update
|
|
Jul 24
|
Ultragenyx to Present GTX-102 Angelman Syndrome Program Update at the ASF Family Conference and Research Symposium
|
|
Jul 22
|
Ionis Pharmaceuticals Surges Into Buy Zone As It, Possibly, Proves Biogen Wrong
|
|
Jul 18
|
Ultragenyx (RARE) Aligns With FDA on Phase III Neuro Study Plans
|
|
Jul 17
|
Ultragenyx Announces Successful End-of-Phase 2 Meeting with FDA for GTX-102 Angelman Syndrome Program
|
|
Jun 14
|
Ultragenyx Announces Pricing of Public Offering of Common Stock and Pre-Funded Warrants
|
|
Jun 13
|
Ultragenyx (RARE) to Seek Accelerated Nod for Rare Disease Drug
|
|
Jun 13
|
Increases to CEO Compensation Might Be Put On Hold For Now at Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE)
|